Candel Therapeutics Presents CAN-3110 Phase 1b Trial Progress at the 5th Annual Glioblastoma Summit

In a recent phase 1b clinical trial, patients received multiple injections of a novel immunotherapy, CAN-3110, developed by Candel Therapeutics. The treatment, aimed at patients with recurrent high-grade glioma (rHGG) after standard care, demonstrated a high level of tolerance with no dose-limiting toxicity observed. Encouraging results from a single dose, which nearly doubled the median overall survival compared to historical data, support the feasibility of repeated doses. The company plans to enroll a second cohort for further study.
CAN-3110, presented at the 5th Glioblastoma Drug Development Summit, is a replication-competent oncolytic virus designed to target cancer cells expressing Nestin. It has shown potential in enhancing survival rates and immune response in patients with rHGG. Positive serology for HSV-1, a feature of the therapy, correlated with better patient outcomes. The trial's findings were published in Nature, and the treatment received Fast Track Designation from the FDA in early 2024.
Candel Therapeutics is advancing CAN-3110 with the goal of initiating a phase 2 trial based on the well-tolerated repeated injections. The company also has a broader focus on creating multimodal biological immunotherapies, with CAN-2409 in trials for various cancers. Their enLIGHTEN™ platform is used for developing new treatments for solid tumors.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!